Eli Lilly and Company announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron, an investigational once-daily oral GLP-1 receptor agonist, for type 2 diabetes management. In ACHIEVE-2, orforglipron (3 mg, 12 mg, 36 mg) was compared to dapagliflozin (10 mg) in adults with type 2 diabetes inadequately controlled on metformin. The trial met its primary endpoint, with orforglipron achieving A1C reductions of up to 1.7% (efficacy estimand) compared to 0.8% for dapagliflozin at 40 weeks.
Women with type 2 diabetes face elevated risks of osteoporosis and fractures, potentially exacerbated by hyperglycemia and medications. Dipeptidyl peptidase-4 inhibitors (DPP4-Is) like sitagliptin may protect bone health by modulating bone metabolism and inflammation, but clinical evidence is sparse. The SLowDOWN trial evaluated the efficacy and safety of sitagliptin on bone mineral density (BMD) and related biomarkers in women with type 2 diabetes over 52 weeks.
On October 8, 2025, the World Health Organization (WHO) released updated guidelines within its consolidated framework on tuberculosis (TB), specifically Module 6: Tuberculosis and Comorbidities, focusing on the critical intersection of TB and undernutrition. Published as part of the WHO’s End TB Strategy, these guidelines address undernutrition as a major global driver of TB, increasing disease susceptibility, worsening treatment outcomes, and contributing to preventable mortality. The recommendations advocate for a people-centered, comprehensive approach to TB care by integrating nutritional interventions to break the cycle of disease and poverty.
The Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), represent a landmark effort by an international multidisciplinary panel of 50+ experts from hepatology, endocrinology, and primary care. Developed via a two-round modified Delphi process (87% agreement threshold) and systematic literature review (up to May 2024), these guidelines update prior NAFLD/NASH frameworks to align with the 2023 nomenclature shift, focusing on cardiometabolic drivers to enhance diagnostic precision and therapeutic equity.
Teva Pharmaceuticals and Medincell announced on October 10, 2025, the U.S. FDA’s approval of an expanded indication for UZEDY® (risperidone) extended-release injectable suspension, now authorized for subcutaneous use as monotherapy or adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder (BD-I) in adults. This marks UZEDY’s second major indication following its 2023 approval for schizophrenia treatment in adults, where it is administered every one or two months.
